[Interchangeability and substitution of biosimilars].

Interchangeabilité et substitution des biosimilaires.
Biosimilar Pharmaceuticals Drug Approval Drug Substitution / methods Europe France Humans Therapeutic Equivalency
Biosimilaires Biosimilars Interchangeability Interchangeabilité Substitution

Journal

Annales pharmaceutiques francaises
ISSN: 0003-4509
Titre abrégé: Ann Pharm Fr
Pays: France
ID NLM: 2985176R

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 25 02 2020
revised: 17 04 2020
accepted: 27 04 2020
pubmed: 11 5 2020
medline: 30 3 2021
entrez: 11 5 2020
Statut: ppublish

Résumé

The rationality of the interchangeability of biosimilars is based on broad scientific evidence and numerous clinical experiences in real life which show no sign of reduced efficacy or different tolerance compared to the original molecule. The substitution of biosimilars (pharmaceutical act) remains widely contested in many countries, notably in France. However, it would make it possible to make very significant savings in a context of major acceleration in health spending. This reluctance is unfounded in light of the quality of biosimilars authorized in Europe and their rigorous evaluation. It is therefore essential to improve the information of health professionals and patients on these biosimilars.

Identifiants

DOI: 10.1016/j.pharma.2020.04.004 PMID: 32387176
pubmed: 32387176
pii: S0003-4509(20)30052-3
doi: 10.1016/j.pharma.2020.04.004
pii:
doi:

Substances chimiques

Biosimilar Pharmaceuticals 0

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

277-284

Informations de copyright

Copyright © 2020 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

A Astier (A)

Biotopic pharmaceuticals, 16, rue Gay-Lussac, 75005 Paris, France. Electronic address: prof.astier@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Mélanges complexes › Produits biologiques › Produits pharmaceutiques biosimilaires › [Interchangeability and substitution of biosimilars].
questionsmedicales.fr › Sciences sociales › Sociologie › Agrément de médicaments › [Interchangeability and substitution of biosimilars].
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Services de santé › Services pharmaceutiques › Ordonnances › Ordonnances médicamenteuses › Substitution de médicament › [Interchangeability and substitution of biosimilars].
questionsmedicales.fr › Régions géographiques › Europe › [Interchangeability and substitution of biosimilars].
questionsmedicales.fr › Régions géographiques › Europe › France › [Interchangeability and substitution of biosimilars].
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › [Interchangeability and substitution of biosimilars].
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Équivalence thérapeutique › [Interchangeability and substitution of biosimilars].